Operator of a pharmaceutical firm intended to develop drugs for submental fat, and fat disorders such as Dercum's disease. The company's drug single injection treatment into subcutaneous fat causes immediate fat cell death at the injection site, enabling patients to a significant reduction of fat tissue for long time periods without any invasive procedures.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series C) | 18-Dec-2019 | $22.1M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
3. Early Stage VC (Series A) | 25-Feb-2016 | 00.00 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
2. Early Stage VC | 10-Jul-2015 | $1.5M | $2.09M | 00.000 | Completed | Clinical Trials - Phase 1 |
1. Early Stage VC | 03-Dec-2012 | $589K | $589K | 00.000 | Completed | Clinical Trials - Phase 1 |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Preferred C | 000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
Preferred B2 | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
Preferred B1 | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
Preferred A2 | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | ||
Preferred A1 | 25,000 | $16.67 | $16.67 | 1x | $16.67 | 3.08% | ||
Preferred A | 75,000 | $7.59 | $7.59 | 1x | $7.59 | 4.61% |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Alon Bloomenfeld | Founder, Chief Executive Officer & Board Member |
Name | Representing | Role | Since |
---|---|---|---|
Adi Goldin | Self | Board Member | 000 0000 |
Alon Bloomenfeld | Raziel Therapeutics | Founder, Chief Executive Officer & Board Member | 000 0000 |
Eyal Lifschitz | Peregrine Ventures | Board Member | 000 0000 |
Philippe Schaison | Raziel Therapeutics | Chairman | 000 0000 |
Shmuel Cabilly Ph.D | Self | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Catalyst Fund | Impact Investing | Minority | 000 0000 | 000000 0 | |
China Everbright | Asset Manager | Minority | 000 0000 | 000000 0 | |
Peregrine Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Quark Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
Wille Finance | Family Office | Minority | 000 0000 | 000000 0 |